Trial Profile

Phase II Study of Evaluation of Fractionated Radio-Immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-Cell Lymphoma.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epratuzumab Y-90 (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms ALYSA

10 Jun 2013 Updated interim results presented at Society of Nuclear Medicine and Molecular Imaging 2013 Annual Meeting, according to an Immunomedics media release.
11 Dec 2012 Updated results were presented at the 2012 Annual Meeting of American Society of Hematology (ASH), according to an Immunomedics media release.
05 Nov 2012 Results have been presented at the 54th American Society of Hematology (ASH) Annual Meeting according to an Immunomedics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com